The use of quantitative patient preference information (PPI) in decision-making has developed substantially over the past few years, particularly in the regulatory setting. There is also a growing interest in incorporating PPI into health technology assessment (HTA). While the extent to which these data are useful from an HTA agency perspective has not always been clear, recent advances suggest that agencies are more interested than ever before. This is exemplified by NICE's recent promotion of their scientific advice on a patient preference study.
The presenters are both active in recent efforts to understand and extend the use of PPI in HTA. Kevin Marsh recently co-chaired an ISPOR working group that reviewed the use of preference information in HTA across Europe. Nigel Cook is a member of IMI PREFER and was the sponsor Principal Investigator on NICE's recent scientific advice on a patient preference study.